Articles tagged with Prostate Tumors
A new animal study suggests that soy isoflavones may slow prostate cancer growth by inhibiting cell proliferation and promoting apoptosis. The study also found lower levels of insulin-like growth factor 1, a hormone that stimulates tumor growth.
Researchers at UNC-CH will investigate prostate cancer mechanisms, including the role of androgens, to develop a potential cure. The team aims to understand why black men develop prostate cancer twice as often as white men do.
Researchers found that losing function of one copy of the PTEN tumor suppressor gene can lead to chronic fatal conditions, including cancer and autoimmune diseases. The study showed that this disruption allows white blood cells to accumulate unchecked and attack their own organs.
Research at Ohio State University found that a low-calorie diet slowed tumor growth in rats and mice with prostate cancer. The study suggested that maintaining proper energy balance may inhibit prostate cancer progression.
ABX-EGF targets the receptor for human epidermal growth factor (EGFr), which is overexpressed on many major human tumor types. The antibody eradicates established tumors with low doses and has minimal immunogenicity.
A new study by USC/Norris Cancer Center scientists raises questions about the potential use of finasteride to prevent prostate cancer. Finasteride, commonly used to treat benign prostate disease, may not be effective as a chemopreventive agent against prostate cancer in men with high PSA levels.
Researchers found that combining low doses of angiostatin with standard radiation therapy improves response rates without increasing toxicity. The combination causes significant growth inhibition in animal models, even in mice with large tumors.
Researchers discovered a new molecular marker, p27(Kip1), that can predict prostate cancer tumor progression and guide treatment decisions. Low levels of the protein are associated with increased disease recurrence and mortality.
A new study by Johns Hopkins researchers found that older men have more extensive prostate disease even if their PSA levels are the same as younger men. The study suggests that age should be an additional guide in deciding whether to do further testing for non-palpable prostate cancer.
Researchers developed a laser-based test to detect early-stage breast and prostate cancer by identifying epithelial cancer cells in blood samples. The test shows promise for predicting disease progression and monitoring treatment response.
The FDA panel unanimously approved a new test for detecting prostate cancer, which catches almost all cancers and reduces unnecessary biopsies. The free PSA test, measuring unbound PSA in the blood, identifies patients who could benefit from surgery or treatments, reducing cancer-free men's biopsies by 20%.
Researchers will present studies on permanent prostate implants and radiation therapy for various cancers, including prostate cancer, lung cancer, and cervical cancer. The presentation highlights the benefits of these treatments in improving survival rates and quality of life for patients.
Researchers found that a lower free-to-total PSA ratio may indicate aggressive prostate cancer. The study suggests this ratio can help doctors distinguish between serious and non-serious cases, leading to better treatment decisions.
Cryosurgery has been used to treat prostate and skin cancers, but recently began treating advanced liver cancer. The procedure freezes tumors using liquid nitrogen, with Emory University Hospital as one of the few medical centers offering it.
Researchers at the University of Chicago Medical Center have found that testosterone can shrink experimental human prostate tumors that no longer depend on the hormone. This suggests a potential new approach for treating advanced prostate cancer.
A multi-institutional study found that surgery is effective for localized prostate cancer, with tumor grade being the best predictor of long-term survival. Ten years after surgery, men with grade 1 tumors had a 6% mortality rate, while those with grade 2 and 3 tumors had 20% and 23% mortality rates, respectively.
Stanford researchers are working on a new PSA test that can distinguish between cancerous and non-cancerous prostate enlargement. By analyzing the PSA protein extracted from enlarged prostates, they aim to eliminate unnecessary biopsies. The team's approach has shown promising results, reducing false positives by up to 86%.